Literature DB >> 10234160

Opportunities for novel therapeutic agents acting at chemokine receptors.

.   

Abstract

Chemokines are proinflammatory mediators that primarily control leukocyte migration into selected tissues and upregulation of adhesion receptors. They also have a role in pathological conditions that require neovascularization and are implicated in the suppression of viral replication. By interaction with their respective G-protein-coupled receptor, chemokines have a profound influence over the selective recruitment of specific cell types in acute inflammatory disease and, hence, inhibition of their action should be of therapeutic benefit. Only now are small molecule inhibitors becoming available to validate this speculation. In this review, without seeking to be comprehensive, the authors provide an introduction to chemokines, their receptors and their role in certain disease processes. Also, recent disclosures claiming novel nonpeptide ligands for chemokine receptors are summarized.

Entities:  

Year:  1999        PMID: 10234160     DOI: 10.1016/s1359-6446(98)01280-x

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

Review 1.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 2.  Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.

Authors:  A M Mfuh; O V Larionov
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 3.  Novel drugs for treating asthma.

Authors:  T T Hansel; P J Barnes
Journal:  Curr Allergy Asthma Rep       Date:  2001-03       Impact factor: 4.806

4.  3D-QSAR studies on CCR2B receptor antagonists: Insight into the structural requirements of (R)-3-aminopyrrolidine series of molecules based on CoMFA/CoMSIA models.

Authors:  Swetha Gade; Shaik Mahmood
Journal:  J Pharm Bioallied Sci       Date:  2012-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.